Cargando…
HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome
BACKGROUND: An association between tumor-specific HMG-CoA reductase (HMGCR) expression and good prognosis has previously been demonstrated in breast and ovarian cancer. In this study, the expression, clinicopathological correlates and prognostic value of HMGCR expression in colorectal cancer was exa...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000148/ https://www.ncbi.nlm.nih.gov/pubmed/24708688 http://dx.doi.org/10.1186/1746-1596-9-78 |
_version_ | 1782313585733533696 |
---|---|
author | Bengtsson, Erik Nerjovaj, Pashtrik Wangefjord, Sakarias Nodin, Björn Eberhard, Jakob Uhlén, Mathias Borgquist, Signe Jirström, Karin |
author_facet | Bengtsson, Erik Nerjovaj, Pashtrik Wangefjord, Sakarias Nodin, Björn Eberhard, Jakob Uhlén, Mathias Borgquist, Signe Jirström, Karin |
author_sort | Bengtsson, Erik |
collection | PubMed |
description | BACKGROUND: An association between tumor-specific HMG-CoA reductase (HMGCR) expression and good prognosis has previously been demonstrated in breast and ovarian cancer. In this study, the expression, clinicopathological correlates and prognostic value of HMGCR expression in colorectal cancer was examined. FINDINGS: Immunohistochemical expression of HMGCR was assessed in tissue microarrays with primary tumours from 557 incident cases of colorectal cancer in the Malmö Diet and Cancer Study. Pearson’s Chi Square test was applied to explore the associations between HMGCR expression and clinicopathological factors and other investigative biomarkers. Kaplan Meier analysis and Cox proportional hazards modeling were used to assess the relationship between HMGCR expression and cancer-specific survival (CSS) according to negative vs positive HMGCR expression. A total number of 535 (96.0%) tumours were suitable for analysis, of which 61 (11.4%) were HMGCR negative. Positive cytoplasmic HMGCR expression was associated with distant metastasis-free disease at diagnosis (p = 0.002), lack of vascular invasion (p = 0.043), microsatellite-instability (p = 0.033), expression of cyclin D1 (p = <0.001) and p21 (p = <0.001). Positive HMGCR expression was significantly associated with a prolonged CSS in unadjusted Cox regression analysis in the entire cohort (HR = 1.79; 95% CI 1.20-2.66) and in Stage III-IV disease (HR = 1.71; 95% CI 1.09-2.68), but not after adjustment for established clinicopathological parameters. CONCLUSIONS: Findings from this prospective cohort study demonstrate that HMGCR is differentially expressed in colorectal cancer and that positive expression is associated with favourable tumour characteristics and a prolonged survival in unadjusted analysis. The utility of HMGCR as a predictor of response to neoadjuvant or adjuvant statin treatment in colorectal cancer merits further study. VIRTUAL SLIDES: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2115647072103464. |
format | Online Article Text |
id | pubmed-4000148 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40001482014-04-26 HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome Bengtsson, Erik Nerjovaj, Pashtrik Wangefjord, Sakarias Nodin, Björn Eberhard, Jakob Uhlén, Mathias Borgquist, Signe Jirström, Karin Diagn Pathol Short Report BACKGROUND: An association between tumor-specific HMG-CoA reductase (HMGCR) expression and good prognosis has previously been demonstrated in breast and ovarian cancer. In this study, the expression, clinicopathological correlates and prognostic value of HMGCR expression in colorectal cancer was examined. FINDINGS: Immunohistochemical expression of HMGCR was assessed in tissue microarrays with primary tumours from 557 incident cases of colorectal cancer in the Malmö Diet and Cancer Study. Pearson’s Chi Square test was applied to explore the associations between HMGCR expression and clinicopathological factors and other investigative biomarkers. Kaplan Meier analysis and Cox proportional hazards modeling were used to assess the relationship between HMGCR expression and cancer-specific survival (CSS) according to negative vs positive HMGCR expression. A total number of 535 (96.0%) tumours were suitable for analysis, of which 61 (11.4%) were HMGCR negative. Positive cytoplasmic HMGCR expression was associated with distant metastasis-free disease at diagnosis (p = 0.002), lack of vascular invasion (p = 0.043), microsatellite-instability (p = 0.033), expression of cyclin D1 (p = <0.001) and p21 (p = <0.001). Positive HMGCR expression was significantly associated with a prolonged CSS in unadjusted Cox regression analysis in the entire cohort (HR = 1.79; 95% CI 1.20-2.66) and in Stage III-IV disease (HR = 1.71; 95% CI 1.09-2.68), but not after adjustment for established clinicopathological parameters. CONCLUSIONS: Findings from this prospective cohort study demonstrate that HMGCR is differentially expressed in colorectal cancer and that positive expression is associated with favourable tumour characteristics and a prolonged survival in unadjusted analysis. The utility of HMGCR as a predictor of response to neoadjuvant or adjuvant statin treatment in colorectal cancer merits further study. VIRTUAL SLIDES: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2115647072103464. BioMed Central 2014-04-07 /pmc/articles/PMC4000148/ /pubmed/24708688 http://dx.doi.org/10.1186/1746-1596-9-78 Text en Copyright © 2014 Bengtsson et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
spellingShingle | Short Report Bengtsson, Erik Nerjovaj, Pashtrik Wangefjord, Sakarias Nodin, Björn Eberhard, Jakob Uhlén, Mathias Borgquist, Signe Jirström, Karin HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome |
title | HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome |
title_full | HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome |
title_fullStr | HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome |
title_full_unstemmed | HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome |
title_short | HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome |
title_sort | hmg-coa reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000148/ https://www.ncbi.nlm.nih.gov/pubmed/24708688 http://dx.doi.org/10.1186/1746-1596-9-78 |
work_keys_str_mv | AT bengtssonerik hmgcoareductaseexpressioninprimarycolorectalcancercorrelateswithfavourableclinicopathologicalcharacteristicsandanimprovedclinicaloutcome AT nerjovajpashtrik hmgcoareductaseexpressioninprimarycolorectalcancercorrelateswithfavourableclinicopathologicalcharacteristicsandanimprovedclinicaloutcome AT wangefjordsakarias hmgcoareductaseexpressioninprimarycolorectalcancercorrelateswithfavourableclinicopathologicalcharacteristicsandanimprovedclinicaloutcome AT nodinbjorn hmgcoareductaseexpressioninprimarycolorectalcancercorrelateswithfavourableclinicopathologicalcharacteristicsandanimprovedclinicaloutcome AT eberhardjakob hmgcoareductaseexpressioninprimarycolorectalcancercorrelateswithfavourableclinicopathologicalcharacteristicsandanimprovedclinicaloutcome AT uhlenmathias hmgcoareductaseexpressioninprimarycolorectalcancercorrelateswithfavourableclinicopathologicalcharacteristicsandanimprovedclinicaloutcome AT borgquistsigne hmgcoareductaseexpressioninprimarycolorectalcancercorrelateswithfavourableclinicopathologicalcharacteristicsandanimprovedclinicaloutcome AT jirstromkarin hmgcoareductaseexpressioninprimarycolorectalcancercorrelateswithfavourableclinicopathologicalcharacteristicsandanimprovedclinicaloutcome |